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Abstract
MicroRNAs (miRNAs) are a recently discovered class of ∼22-nucleotide regulatory RNAs that post-
transcriptionally regulate gene expression. We have recently demonstrated that muscle-specific
miRNAs miR-1 and -133 play an important role in modulating muscle proliferation and
differentiation. Here, we investigate the involvement of miRNAs in cardiac hypertrophy. We
analyzed the global expression of miRNAs in agonist-induced hypertrophic cardiomyocytes as well
as in pressure overload-induced hypertrophic hearts and found the miRNA expression profile altered
in those hypertrophic conditions. We further show that inhibition of endogenous miR-21 or -18b
augments hypertrophic growth. Conversely, introduction of functional miR-21 or -18b into
cardiomyocytes represses myocyte hypertrophy. Together, our studies point to miRNAs as critical
regulators of cardiac hypertrophy.
INTRODUCTION
microRNAs (miRNAs) are a class of short, non-coding RNA molecules that have recently
emerged as important regulators of gene expression [1]. Many miRNAs are highly
evolutionarily conserved and more than 400 miRNAs are known to exist in humans alone
[1]. miRNAs negatively regulate target gene expression through miRNA complementarity to
target sequence(s) within the 3’ untranslated region of target mRNAs through translational
repression or by degradation of bound RNA [1-3]. Recently, we and others have demonstrated
that a subset of muscle-specific miRNAs, miR-1 and miR-133 in particular, play important
roles in muscle cell proliferation and differentiation [4,5]. Given that miRNAs participate in
such fundamental processes, we investigated the potential role for miRNAs in regulating the
well-documented changes in gene expression that occur during cardiac hypertrophy.
In this report, we show that the expression of a subset of miRNAs is altered in hypertrophic
cardiomyocytes. Interestingly, we found more miRNAs that are up-regulated than down-
regulated in response to cardiac hypertrophy. We have used both overexpression and
knockdown approaches to demonstrate that miR-18b and miR-21 repress hypertrophy in
neonatal rat cardiomyocyte in vitro.
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Cardiomyocyte tissue culture and transfection
Preparation of neonatal rat cardiomyocytes was as described [6,7]. LNA oligonucleotides and
miRNA duplexes were transfected using Lipofectamine. Hypertrophic stimuli used: PE (100
μM), LIF (1,000 units/ml) and fetal bovine serum (FBS) 10%.
Analysis of microRNA expression by microarray
Total RNA was isolated from rat neonatal cardiomyocytes and mouse heart tissue (Trizol).
Microarray production and hybridization methods have been described [8]. Five micrograms
of labeled RNA from each treatment were hybridized to a microRNA microarray with 560
mouse and human miRNAs and analyzed using GenePix Pro (Axon Instruments). Median pixel
intensity values were background subtracted and log-transformed (base 2). Significant
Analysis of Microarray (SAM, Stanford University) was used to determine statistically
significant changes in miRNA expression between treatments (q-value threshold < 0.05).
microRNA Northern Blot, RT-PCR analysis and immunocytochemistry
microRNA Northern Blot analyses were as described [4]. Semi-quantitative RT-PCR and
immunocytochemical analyses were essentially as described [7]. For cell size measurement,
∼200 cardiomyocytes stained with anti-α-actinin antibody from each treatment were randomly
chosen for surface area measurement using a computerized morphometric system (ImageJ).
Data were presented as average ± SEM. Student’s t test was used for statistical analysis. A
PCR method to detect mature miRNAs was adapted with minor modification [9]. Total RNA
was DNAse I treated, phenol-chloroform extracted, precipitated and dissolved in DEPC water.
RNA was polyadenylated, then reversed-transcribed using an oligo(dT) adapter primer.
Resulting cDNA was used in a PCR reaction with oligonucleotide primers complementary to
the oligo(dT) adapter primer and to miR-18b. PCR products were resolved on a 15% acrylamide
gel with a 10 bp DNA ladder.
Pressure-overload hypertrophy models
Male C57BL6 mice (6-8 wk old) were subjected to pressure overload by thoracic aortic banding
(TAB) [10]. Mice were sacrificed after 2 wk or 4 wk banding and hearts harvested for RNA
extraction.
RESULTS AND DISCUSSION
Global analysis of miRNA expression during cardiac hypertrophy
To better understand the role of miRNAs in cardiac hypertrophy, we sought to identify miRNAs
involved in cardiac hypertrophy using a custom miRNA microarray screening approach [4,
8]. Using this sensitive and quantitative high-throughput technology, we profiled global
miRNA expression in phenylephrine (PE)-treated neonatal cardiomyocytes (Figure 1A) and
in mouse hearts subjected to pressure overload by thoracic aortic banding (TAB) (Figure 1B
and F), and found the expression signatures of several miRNAs were altered during cardiac
hypertrophy.
Northern blot analysis for several miRNAs confirmed the results from the miRNA microarray
screening (Figure 1C and D). The expression of miR-21, -23a, and 125b is increased in agonist-
induced hypertrophic cardiomyocytes and in the TAB-induced hypertrophic hearts. Whereas
the expression of miR-25 and -29a is very low in neonatal cardiomyocytes and appears
unchanged during hypertrophy in vitro (Figure 1C), their expression is drastically up regulated
in TAB-induced hypertrophic hearts (Figure 1D). Interestingly, miR-18b is among the most
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highly induced miRNAs in both in vitro and in vivo hypertrophy models (Figure 1), however,
we were unable to confirm its expression by Northern analysis, due to its low expression in
cardiomyocytes (data not shown). We applied a technique designed to detect expression of a
mature miRNA by PCR [9], which confirmed increased miR-18b expression in response to
hypertrophic stimuli (Figure 1E).
Inhibition of cardiomyocyte hypertrophy by miR-21 and miR-18b
To explore the potential involvement of miRNAs in the regulation of cardiomyocyte
hypertrophy, we specifically inhibited miR-21 and -18b in neonatal rat cardiomyocytes using
locked nucleic acid (LNA)-modified antisense oligonucleotides [11]. While miR-21 represents
an abundantly expressed miRNA (Figure 1C), miR-18b expression was very low in the
cardiomyocytes (Figure 1E). When LNA oligonucleotides antisense (miR-LNA) to miR-21 or
miR-18b were transfected into cardiomyocytes, we consistently observed induction of
hypertrophy, including increased cardiomyocyte size (Figures 2A and B) and induction of
hypertrophic markers such as ANF, α-actinin and skeletal muscle α-actin (Figures 2C-E).
Those changes are subtle yet reproducible. The role for miR-18b and 21 in hypertrophy is
further supported by a gain-of-function approach whereby we transfected cardiomyocytes with
short double-stranded RNAs (miR-duplexes), in which a single-strand identical to mature
miR-21 or - 18b is incorporated into the RISC complex [3,12]. Transfection of miR-21 and
miR-18b duplexes slightly decreased cardiomyocyte size and decreased expression of
hypertrophic markers (Figures 2A-E). Interestingly, transfection of miR-21 duplexes, but not
miR-18b duplexes, inhibited PE-induced cardiomyocyte hypertrophy (Figure 2B), suggesting
distinct functions for these two miRNAs in hypertrophic growth. Collectively, these data
suggest that miR-21 and -18b may play a causative role in cardiomyocyte hypertrophy.
Emerging evidence has pointed to the critical role of miRNAs in variety of biological processes.
As an initial step to explore the potential involvement of miRNAs in the pathophysiology of
cardiac function, we profiled the changes of miRNA expression in both in vitro and in vivo
cardiac hypertrophy models. Our results demonstrate that many miRNAs are regulated during
cardiac hypertrophy and we show that miR-18b and miR-21 play a critical role in the
hypertrophic process. Our data are consistent with two recent reports that identified
dysregulated miRNA expression during cardiac hypertrophy and documented important roles
for miR-1 and miR-195 in cardiac hypertrophy and heart failure [13,14].
We have found that miR-21 expression was induced during hypertrophy and, most importantly,
our studies suggest that miR-21 may negatively regulate cardiac hypertrophy. Recent studies
have found that miR-21 is likely involved in tumor-related cell growth and apoptosis [4,15,
16]. Interestingly, some of those reports appear contradictory: while one study documented
that miR-21 inhibition provoked cell growth in HeLa cells [16], others showed that miR-21
inhibition led to activation of apoptosis and decreased cell proliferation [4,15]. Clearly, the
identification of the miR-21 regulatory targets and understanding the molecular pathways
modulated by miR-21 in different biological systems will be the key to our understanding the
biological function of this miRNA.
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Microarray screen identifies miRNAs that are regulated during cardiac hypertrophy. (A) Up-
and down-regulated miRNAs in phenylephrine (PE) treated neonatal cardiomyocytes. (B) Fold
change of miRNA expression in 2 week thoracic aortic banding (TAB) hearts. (C) Northern
blot analysis of miRNAs using equal amounts of total RNA isolated from rat neonatal
cardiomyocytes treated with various hypertrophic stimuli. PE, phenylephrine; LIF, leukemia
inhibitory factor; FBS, fetal bovine serum. (D) Northern blot analysis of miRNAs using equal
amounts of total RNA isolated from control, 2 week, or 4 week TAB mice. tRNAs were used
as a loading control. (E) RT-PCR analysis for miR-18b expression in PE or LIF treated
cardiomyocytes. U6 expression served as control. (F) Gross heart morphology of sham, 2 and
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4 week TAB hearts, and RT-PCR analysis for hypertrophic genes using total RNA isolated
from those conditions. GAPDH served as control.
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miR-18b and miR-21 regulate cardiomyocyte hypertrophy. (A) Representative images of α-
actinin-stained cardiomyocytes transfected with LNA antisense oligonucleotides against
indicated miRNAs (upper panels) or miR-duplexes (lower panels). GFP was used as a control.
(B) Quantitative analysis of cardiomyocyte cell size. ∼200 cells immunostained with anti-α-
actinin antibody from each treatment were randomly chosen for surface area measurement.
Results presented as relative cell area compared to controls. (C and D) RT-PCR analysis of
hypertrophic marker genes ANF and skeletal muscle α-actin (sk-α-actin) using total RNA
isolated from cardiomyocytes treated with indicated LNA oligos, or miRNA duplexes. (E)
Western blot analysis of α-actinin expression in cardiomyocytes treated with indicated LNA
oligos, miRNA duplexes, or GFP. β-tubulin serves as a loading control. Error bars represent
standard deviation; * p < 0.05; ** p < 0.01.
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